ESSA Pharma - About the company
ESSA Pharma is an acquired company based in Vancouver (Canada), founded in 2009. It operates as a Developer of small molecule drugs for the treatment cancer. ESSA Pharma has raised $16.4M in funding from Deerfield and Special Situations Fund. The company has 3349 active competitors, including 1124 funded and 781 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, BeiGene and Sana Biotechnology.
Company Details
Developer of small molecule drugs for the treatment of cancer. The company is developing drugs that selectively block the N-terminal domain of the androgen receptor (AR), which has been indicated in the growth and survival of most prostate cancer. The product pipeline includes EPI-7386 for metastatic Castration-resistant Prostate cancer (CRPC). and it is also developing drugs for breasts cancer.
- Website
- essapharma.com
- Social
- Email ID
- *****@essapharma.com
Key Metrics
Founded Year
2009
Location
Vancouver, Canada
Stage
Acquired
Total Funding
$16.4M in 10 rounds
Latest Funding Round
Ranked
234th among 3349 active competitors
Employee Count
15 as on Aug 31, 2026
Investment & Acquisitions
Similar Companies
Exit Details
Acquired by Alexis Bio (Jul 14, 2025)
Legal entities associated with ESSA Pharma
ESSA Pharma is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Documents |
|---|---|---|---|---|
ESSA PHARMA INC. CIN: 1633932 , United States, Active | - | - | - |
ESSA Pharma's acquisition details
ESSA Pharma got acquired by Alexis Bio on Jul 14, 2025.
Click here to take a look at ESSA Pharma's acquisition in detail
Sign up to download ESSA Pharma's company profile
ESSA Pharma's funding and investors
ESSA Pharma has raised a total funding of $16.4M over 10 rounds. Its first funding round was on Jul 2014. Its latest funding round was a Post IPO round on Jan 12, 2021 for $*****. 1 investor participated in its latest round. ESSA Pharma has 11 institutional investors.
Here is the list of recent funding rounds of ESSA Pharma:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 12, 2021 | 4052782 | Post IPO | 6972042 | 6005010 | 8506125 | 5957721 |
Jan 16, 2018 | 3760880 | Post IPO | 2401658 | 8596507 | 8955250 | |
Jan 09, 2018 | 3595315 | Post IPO | 6334217 | 3489982 | 3872263 | 6469997 |
Access funding benchmarks and valuations. Sign up today!View details of ESSA Pharma's funding rounds and investors
ESSA Pharma's founders and board of directors
Founder? Claim ProfileESSA Pharma's employee count trend
ESSA Pharma has 15 employees as of Aug 26. Here is ESSA Pharma's employee count trend over the years:
Uncover ESSA Pharma's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
ESSA Pharma's Competitors and alternates
Top competitors of ESSA Pharma include Jazz Pharmaceuticals, BeiGene and Sana Biotechnology. Here is the list of Top 10 competitors of ESSA Pharma, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 81/100 | |
2nd |  BeiGene 2010, Cambridge (United States), Public | Developer of targeted and immune-oncology drugs against cancer | $172M | 81/100 | |
3rd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of engineered cell therapies for treating various human diseases | $821M | 74/100 | |
4th | Ideaya Biosciences 2015, San Francisco (United States), Public | Developer of oncology-focused precision medicine using molecular diagnostics | $157M | 73/100 | |
5th | Senti Bio 2016, San Francisco (United States), Public | Developer of cell and gene therapies for patients living with incurable diseases | $158M | 72/100 | |
6th | Sutro Biopharma 2003, United States, Public | Developer of antibody-based therapeutics for cancer therapy | $175M | 72/100 | |
7th | Syndax 2005, Waltham (United States), Public | Developer of targeted therapies for the treatment of cancer | $198M | 72/100 | |
8th | Developer of T-cell therapies for the treatment of cancer | $49.8M | 72/100 | ||
9th |  Moderna 2010, Cambridge (United States), Public | Developer of mRNA-based therapeutics for a wide range of diseases | $2.78B | 72/100 | |
10th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 71/100 | |
234th | ESSA Pharma 2009, Vancouver (Canada), Acquired | Developer of small molecule drugs for the treatment cancer | $16.4M | 58/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on ESSA Pharma's competitors? Click here to see the top ones
ESSA Pharma's Investments and acquisitions
ESSA Pharma has acquired Realm Therapeutics. ESSA Pharma has not made any investments as of now.Reports related to ESSA Pharma
Here is the latest report on ESSA Pharma's sector:
News related to ESSA Pharma
Filter this listMedia has covered ESSA Pharma for a total of 4 events in the last 1 year.
•
Siskinds LLP Investigates Essa Pharma for Potential Class ActionCNW•Dec 05, 2025•ESSA Pharma, Siskinds
•
ESSA Announces Completion of Arrangement with XenoTherapeuticsPR Newswire•Oct 09, 2025•ESSA Pharma, XenoTherapeutics
•
•
ESSA Pharma Amends Agreement with XenoTherapeutics; Shareholders to Receive $0.12/ShareCNW•Sep 24, 2025•ESSA Pharma, XenoTherapeutics
•
ESSA Pharma Inc. Adjourns Special Meeting to September 29 for XenoTherapeutics Transaction DiscussionsPR Newswire•Sep 10, 2025•ESSA Pharma, XenoTherapeutics
•
ESSA Pharma Clarifies Nasdaq Due Bill Trading for Cash DistributionPR Newswire•Aug 26, 2025•ESSA Pharma
•
Essa Pharma Announces US$80 Million Cash Distribution to ShareholdersPR Newswire•Aug 07, 2025•ESSA Pharma
•
Halper Sadeh LLC Investigates SPTN, BGSF, COOP, EPIX on Behalf of ShareholdersPR Newswire•Aug 02, 2025•Halper Sadeh, BGSF, Mr. Cooper Group, ESSA Pharma and 5 others
•
Legal Inquiry for Mergers: MGRM, EPIX, BLBX, and PBBKPR Newswire•Jul 19, 2025•Monogram Technologies, ESSA Pharma, Black Box Stocks, Presence Bank and 1 other
•
XenoTherapeutics to Acquire ESSA Pharma in Deal Backed by XOMA RoyaltyCanadianlawyermag•Jul 16, 2025•XenoTherapeutics, ESSA Pharma, XOMA Corporation
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about ESSA Pharma
Explore our recently published companies
- Online Converter - Unfunded company
- MTI Education - Russia based, Unfunded company
- Big Tree Entertainment - Mumbai based, 1999 founded, Series D company
- Das Pendawala Foods Pvt - 2009 founded, Unfunded company
- Tsoft IT - Bangladesh based, 2015 founded, Unfunded company
- Linde Homecare - France based, Unfunded company
